Delivery Order 36C24226D0040-36C24226N0388
- Not listed
- Sofie CO., doing business as IBA Molecular, was awarded a delivery order valued at $1,176,442.72 on September 1, 2025, by the Department of Veterans Affairs through Veterans Integrated Service Network 17 (VISN 17) for the supply of PYLARIFY (piflufolastat F-18), a positron emission tomography imaging agent used in prostate cancer detection. This firm fixed-price delivery order, with an ultimate completion date of August 31, 2026, carries no set-aside designation and will be performed in...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 2 (VA - VHA) awarded a $383,846.78 delivery order contract to Sofie CO., doing business as Sofie, a subsidiary of Sofie Biosciences, Inc., to provide PET radiopharmaceuticals. The firm fixed price contract runs from April 15, 2022 to April 15, 2023 and will be performed in Sterling, Virginia. PET radiopharmaceuticals are medical imaging radioisotopes that are used with positron emission...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 10 awarded a $1.34 million firm fixed price delivery order contract to Sofie CO., doing business as Sofie, a subsidiary of Sofie Biosciences, Inc. The five year contract is for radiopharmaceutical PET imaging services to be performed in Sterling, Virginia. As the prime contractor, Sofie will provide radiopharmaceutical production and distribution to support positron emission tomography scans for...
- This is a delivery order awarded to Sofie CO., doing business as IBA Molecular, by the Veterans Integrated Service Network 2 (VISN 2) of the U.S. Department of Veterans Affairs (VA). The contract is for the delivery of pet radiopharmaceuticals to the Buffalo VA Medical Center, with a ceiling value of $955,896.40 and a period of performance through April 14, 2026. The contract is a firm fixed-price delivery order, without any set-aside designation. Sofie CO. is a for-profit organization that...
- This federal contract award to Sofie CO., a subsidiary of Sofie Biosciences, Inc., provides PET/CT radiopharmaceuticals to the Department of Veterans Affairs (VA). The $2,343,583.08 fixed-price contract was set aside for small businesses and is scheduled for completion by September 30, 2023. Sofie CO. is a specialized manufacturer and supplier of molecular diagnostics and therapeutics, with extensive experience in positron emission tomography (PET) imaging. The company has been a key provider of...
- This contract award to Sofie CO., doing business as Sofie, is for the supply of radiopharmaceuticals to the U.S. Department of Veterans Affairs (VA). The $171,500.00 firm fixed-price purchase order has an ultimate completion date of April 4, 2019 and was awarded on October 1, 2016. This contract is not set aside and is part of Sofie's broader portfolio of federal contracts and indefinite delivery vehicles (IDVs) to supply specialized radiopharmaceuticals, including PET imaging agents and...
- The Department of Veterans Affairs, Veterans Integrated Service Network (VISN) 10, awarded Sofie CO., operating as IBA Molecular, a $610,725.04 firm fixed-price purchase order on October 1, 2024, for PET MRI radiopharmaceuticals to support the John D. Dingell VA Medical Center in Detroit, Michigan. This award was issued without a set-aside designation following a sole source procurement notice published in September 2024. The VA determined that Sofie CO. was the only vendor capable of...
- Sofie CO., operating under the brand name IBA Molecular, received a delivery order award from Veterans Integrated Service Network 15 (VISN 15) on June 1, 2024, for the supply of PYLARIFY F-18 DCFPYL, a radiopharmaceutical used in positron emission tomography (PET) imaging. The contract is structured as a firm fixed-price delivery order with a ceiling value of $1.35M and an ultimate completion date of May 31, 2025. This award carries no set-aside designation, reflecting the contractor's...
- This federal contract award to Sofie CO. (doing business as Sofie), a subsidiary of Sofie Biosciences, Inc., was issued by the Veterans Integrated Service Network 10 (VISN 10) of the Department of Veterans Affairs (VA). The $1,306,250.00 delivery order is to exercise Ordering Period 2 and add 64 doses of a radiopharmaceutical PET product. The contract is a firm fixed-price award, with no set-aside designation. Sofie is an experienced supplier of radiopharmaceuticals, pharmaceuticals, and related...
- This is a federal contract award from the Department of Veterans Affairs (VA) to Sofie CO., doing business as Sofie, a subsidiary of Sofie Biosciences, Inc. The contract is for the delivery of PET radiopharmaceuticals, which are specialized imaging agents used for medical diagnostics and cancer treatment. The award, valued at $188,258.00, is a delivery order under a larger $5.86 million Indefinite Delivery Vehicle (IDV) contract with the VA's Veterans Integrated Service Network (VISN) 15 for the...
- 36C24226D0040Indefinite Delivery Contract
- 36C24226D0040-36C24226N0388Delivery Order
Sofie CO., doing business as IBA Molecular, was awarded a $830,796.45 firm fixed-price delivery order on March 15, 2026, for the supply of Positron Emission Tomography (PET) radiopharmaceuticals to support the Veterans Integrated Service Network 2 (VISN 2). The contract, which carries no set-aside designation, has an ultimate completion date of March 14, 2027, with performance occurring in Sterling, Virginia. The award represents a delivery order under an existing indefinite delivery vehicle, reflecting the Department of Veterans Affairs' established relationship with Sofie CO. as a specialized supplier of diagnostic radiopharmaceuticals for cancer detection and neurological imaging applications across the VA healthcare system. Sofie CO. is a subsidiary of Sofie Biosciences, Inc., headquartered in Sterling, Virginia, and specializes in the development and manufacturing of molecular diagnostic and therapeutic radiopharmaceuticals. The company maintains an extensive portfolio of federal contracts with the Department of Veterans Affairs and Defense Health Agency, supplying critical products including PYLARIFY (piflufolastat F-18) for prostate cancer detection, NEURACEQ (florbetaben F-18) for Alzheimer's disease imaging, F-18 fluorodeoxyglucose (FDG) for oncology applications, and various gallium-68 radiopharmaceuticals. The company holds multiple master indefinite delivery contracts and blanket purchase agreements with federal agencies, including a $1.93 million IDV with VISN 2 awarded in April 2025, establishing long-term procurement relationships that enable streamlined supply of essential radiopharmaceuticals to VA medical centers nationwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $830.8k | 3/4/26 |